3 reports

Announcement (May ##, 2007): Cortex Pharmaceuticals, Inc. and The University of Alberta have entered into an exclusive patent license agreement to broaden the use of Cortex' s AMPAKINEr technology to prevent and treat opiate- and barbiturate-induced respiratory depression.

  • Pharmaceutical
  • United States
  • Corporate Finance
  • M&A
  • Cortex

The company markets a range of antibiotics, barbiturates, and other prescription medicines.

  • Pharmaceutical
  • Therapy
  • Corporate Finance
  • M&A
  • Cephalon, Inc.

The company' s First Check ## Drug Test screens for five prescription drugs: Benzodiazepines, Barbiturates, Methadone, Oxycodone and Tri-cyclic Antidepressants; and seven illicit drugs: Marijuana, Cocaine, Ecstasy, Phencyclidine, Amphetamine, Opiates and Methamphetamine.

  • Diagnostics
  • Healthcare
  • Pharmaceutical
  • M&A
  • Alere Inc.